Evidence map›Paper›PMID 40819114›Full record

ReviewCancer gene therapy2025

LncSNHGs: new targets in osteosarcoma.

Yining Zhang, Jinfa Wu, Jiaming Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yining ZhangDepartment of Orthopaedic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Jinfa WuDepartment of Orthopaedic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Jiaming LiuDepartment of Orthopaedic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China. liujiamingdr@hotmail.com.ORCID http://orcid.org/0000-0001-8444-9136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have attracted significant attention for their role in tumor initiation and progression. Specifically, studying lncRNA small nucleolar RNA host genes (lncSNHGs) has opened up new possibilities for the treatment of osteosarcoma (OS). This review aims to give a thorough overview of the state of research on the biological roles, molecular mechanisms, and expression of the lncRNA SNHG family in OS. Through an extensive analysis, it is demonstrated that members of the SNHG family exhibit dysregulated expression patterns in OS. These dysregulations affect multiple oncogenic processes, including tumor proliferation, metastasis, apoptosis, autophagy, and chemotherapy resistance. The lncRNA SNHG family promises to identify novel strategies and targets for diagnosing, treating, and prognosis OS.

Indexed as

Bone NeoplasmsOsteosarcomaRNA, Long NoncodingAnimalsGene Expression Regulation, NeoplasticHumansPrognosisRNA, Long Noncoding

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.